Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
April 23, 2020

Europe’s medical devices industry sees a drop of 10.8% in deal activity in Q1 2020

Europe’s medical devices industry saw a drop of 10.8% in overall deal activity during Q1 2020, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 74 deals worth $12bn were announced for the region during Q1 2020, against the last four-quarter average of 83 deals.

Of all the deal types, venture financing saw most activity in Q1 2020 with 37, representing a 50% share for the region.

In second place was M&A with 31 deals, followed by private equity deals with six transactions, respectively capturing a 41.9% and 8.1% share of the overall deal activity for the quarter.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $11.8bn, while venture financing and private equity deals totalled $194.04m and $9.88m, respectively.

Europe medical devices industry deals in Q1 2020: Top deals

The top five medical devices deals accounted for 98.01% of the overall value during Q1 2020.

The combined value of the top five medical devices deals stood at $11.76bn, against the overall value of $12bn recorded for the quarter.

The top five medical devices industry deals of Q1 2020 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $11.5bn acquisition of Qiagen

2) The $121.9m acquisition of EOS imaging by Alphatec Holdings

3) InVitae’s $95m acquisition of Diploid

4) The $23.73m venture financing of Lunaphore Technologies by Alpana Ventures, Occident Group, PHC and Redalpine Venture Partners

5) Zealand Pharma’s acquisition of Valeritas Holdings for $23m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.


Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy